International Assets Investment Management LLC Purchases 8,950 Shares of United Therapeutics Co. (NASDAQ:UTHR)

International Assets Investment Management LLC boosted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13,769.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,015 shares of the biotechnology company's stock after buying an additional 8,950 shares during the period. International Assets Investment Management LLC's holdings in United Therapeutics were worth $1,982,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Blue Trust Inc. grew its stake in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company's stock valued at $114,000 after buying an additional 46 shares during the period. Formidable Asset Management LLC grew its stake in United Therapeutics by 1.5% in the third quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company's stock valued at $821,000 after acquiring an additional 53 shares during the period. Alaska Permanent Fund Corp increased its holdings in shares of United Therapeutics by 1.7% during the third quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company's stock valued at $752,000 after acquiring an additional 57 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC raised its position in shares of United Therapeutics by 6.1% during the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 73 shares during the period. Finally, E Fund Management Co. Ltd. lifted its holdings in shares of United Therapeutics by 3.9% in the 3rd quarter. E Fund Management Co. Ltd. now owns 2,032 shares of the biotechnology company's stock worth $459,000 after purchasing an additional 77 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on UTHR. The Goldman Sachs Group upped their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a "neutral" rating in a report on Friday, May 3rd. Oppenheimer lifted their price target on United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research note on Thursday, May 2nd. Leerink Partnrs reissued an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. Wells Fargo & Company raised their target price on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Finally, Wedbush reiterated an "outperform" rating and set a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $308.78.

United Therapeutics Stock Performance

NASDAQ:UTHR traded up $0.07 during trading on Monday, reaching $264.34. The company's stock had a trading volume of 349,600 shares, compared to its average volume of 463,043. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $269.81. The firm has a market cap of $11.73 billion, a price-to-earnings ratio of 12.50 and a beta of 0.54. The firm has a 50 day moving average of $240.51 and a 200-day moving average of $230.69. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm's revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.86 earnings per share. Research analysts expect that United Therapeutics Co. will post 24.2 EPS for the current fiscal year.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $264.22, for a total value of $951,192.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company's stock, valued at $34,348.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $264.22, for a total transaction of $951,192.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $34,348.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company's stock, valued at $30,756.70. The disclosure for this sale can be found here. Insiders sold 151,230 shares of company stock valued at $36,040,995 in the last three months. Company insiders own 12.50% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.